ClinicalTrials.gg
Not yet recruitingNCT07888218DEEPLAIMUpdated Oct 22, 2026

Replacing Spatial Filtering With Deep-learning Noise Reduction

An observational study in Cardiac Disease, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Central Hospital, Nancy, France · Observational

Updated Oct 22, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
49
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Spatial filtering is routinely required to reduce the statistical noise of gated SPECT myocardial perfusion imaging, but at the expense of image blurring. This study will evaluate a deep-learning-based noise reduction (DLNR) approach, developed to shorten acquisition times, when used as a replacement for conventional spatial filters (CSF).

Read the detailed description

SPECT image noise can also be reduced using deep-learning algorithms, which were initially developed to enable shorter acquisition times or lower injected activities while maintaining diagnostic image quality. More recently, when used alone rather than in combination with spatial filters, such an algorithm was shown to outperform the spatial filters previously required for bone SPECT, providing greater noise reduction with substantially less smoothing. This raises the question of whether the same approach could be applied to gated-SPECT images acquired with low-dose protocols.

02

Conditions studied

  • Cardiac Disease

Browse trials for

03

In context

Heart Diseases

3,674 studies on the registry are indexed under Heart Diseases; 458 are open to participants now.

This study's planned enrollment of 49 is below the median of 295 across 1,250 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 796 studies on the registry; 187 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients referred for myocardial scintigraphy due to known or suspected coronary artery disease, who underwent the same one-day "low-dose" protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients who underwent myocardial scintigraphy at the Nancy University Hospital (CHRU) under the conditions applicable to the groups described above.

Exclusion criteria

Exclusion Criteria:

  • Significant arrhythmia, technical reconstruction issues, poor image quality (motion artifacts during acquisition, insufficient count statistics).
  • Patients who objected to the use of their data for research purposes.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
49 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Compare deep learning-based noise reduction and conventional spatial filters for myocardial scintigraphy image reconstruction.

    Experienced physicians will perform a visual analysis of the images reconstructed with and without deep learning and will complete a questionnaire that includes an image quality and interpretation score.

    Time frame: Day 1

Secondary outcomes

  1. Compare left ventricle end-diastolic and end-systolic volumes and Left Ventricle Ejection Fraction between deep learning and conventional filters

    Image quality: visual scale of cine loops for the two observers, categorized as good-to-excellent (low background noise, good edge definition), intermediate, or poor (very high background noise, edge definition making analysis difficult or impossible).

    Time frame: Day 1

07

Study locations

1 site
  • Chru Nancy
    Vandœuvre-lès-Nancy, 54511, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 22, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Jan 23, 2027
CompletionEst.
Mar 3, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07888218
Responsible party
Pierre Yves MARIE (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Oct 22, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Jan 23, 2027 (estimated)
Completion
Mar 3, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Pierre-Yves Marie, MD,PhD
Contact
py.marie@chru-nancy.fr
0383153909 ext. +33
Véronique Roch, MSc
Contact
v.roch@chru-nancy.fr
0383154276 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion